Molecular basis of inhibition of the amino acid transporter B<sup>0</sup>AT1 (SLC6A19).

Xu, Junyang; Hu, Ziwei; Dai, Lu; Yadav, Aditya; Jiang, Yashan; Bröer, Angelika; Gardiner, Michael G; McLeod, Malcolm et al. · Nat Commun · 2024

basic_science · Level V

Where this comes from

Abstract

The epithelial neutral amino acid transporter B<sup>0</sup>AT1 (SLC6A19) is the major transporter for the absorption of neutral amino acids in the intestine and their reabsorption in the kidney. Mouse models have demonstrated that lack of B<sup>0</sup>AT1 can normalize elevated plasma amino acids in rare disorders of amino acid metabolism such as phenylketonuria and urea-cycle disorders, implying a pharmacological approach for their treatment. Here we employ a medicinal chemistry approach to generate B<sup>0</sup>AT1 inhibitors with IC<sub>50</sub>-values of 31-90 nM. High-resolution cryo-EM structures of B<sup>0</sup>AT1 in the presence of two compounds from this series identified an allosteric binding site in the vestibule of the transporter. Mechanistically, binding of these inhibitors prevents a movement of TM1 and TM6 that is required for the transporter to make a conformational change from an outward open state to the occluded state.

Medical subject headings